CVS Health Corporation (CVS)
What's Shaping CVS' Health Care Benefits Arm for the Rest of 2025?
CVS Health's Health Care Benefits arm posts solid Medicare gains and prepares for an ACA exit with a $448M reserve.
Here's Why CVS Health (CVS) is Poised for a Turnaround After Losing 7.7% in 4 Weeks
CVS Health (CVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CVS Health Has Become A Strong GARP Pick (Rating Upgrade)
This article upgrades my rating on CVS Health to 'Buy' as recent negative industry headlines have pressured its valuation. These negatives are fully priced in already, creating a strong GARP (growth at a reasonable price) opportunity. Despite margin pressures, robust EPS growth is projected at double-digit rates. Yet, the forward P/E is just 10x.
Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
CVS Health - Q2 Earnings Are A Referendum On Future Of Company
CVS has transformed from a retail pharmacy to a complex healthcare conglomerate, but its stock price has remained stagnant over the past decade. The Medicare Advantage business, once seen as a growth engine, has become less profitable, leading to management shakeups and activist investor intervention. Despite a short-term recovery in 2025, CVS faces ongoing challenges: declining retail, regulatory threats to PBM, and uncertain Medicare Advantage profitability.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?
CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.
Here's Why CVS Health (CVS) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
CVS Health (CVS) Stock Falls Amid Market Uptick: What Investors Need to Know
CVS Health (CVS) closed at $66.6 in the latest trading session, marking a -4.28% move from the prior day.
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Brokers Suggest Investing in CVS Health (CVS): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
